



**DBW-014-1102001**      Seat No. \_\_\_\_\_

**M. Pharm. (Sem. II) (Regulatory Affairs)**  
**(W.E.F. 2017) Examination**

**July - 2022**

**Regulatory Aspects of Drugs & Cosmetics : MRA-201T**

**Faculty Code : 014**  
**Subject Code : 1102001**

**Time : 3 Hours] [Total Marks : 75**

**Instructions :** (1) Figures to the right indicate full marks.  
(2) Draw neat and clean diagram wherever required.

**1 Answer the following questions :  $10 \times 2 = 20$**

- (1) What is Active Substance Master File ?
- (2) Give the full form of SNDA, FFDCA, PANDRH and ASEAN.
- (3) Enlist content of IMPD as per EU.
- (4) What is Rest of the World Market ? Describe in brief with its classification.
- (5) What is CEP ? Describe in brief.
- (6) What is 180 day exclusivity ?
- (7) What does qualified person mean in EU ? Enlist his/her duties.
- (8) Give the name of any 6 CFRs given by USFDA.
- (9) What are the regulatory authorities of Canada, South Korea, Saudi Arabia and Australia ?
- (10) What is purple book ?

**2 Answer any **two** out of the following :  $2 \times 10 = 20$**

- (1) Explain in details about the Hatch Waxman act, its procedure and loopholes.
- (2) Write a note on Drug Master File.
- (3) Describe the details about different types of NDA applications and its approval process in US.

**3** Answer any **seven** out of the following : **7×5=35**

- (1) Describe the post marketing surveillance of drugs in Japan.
- (2) Write down the organizational structure of PMDA.
- (3) What are the differences between CTD and ACTD ?
- (4) Write a short note on APEC and EAC.
- (5) What are Cosmetics ? Explain in details about the Federal Register.
- (6) Write a brief note on changes to an approved NDA/ANDA.
- (7) Give the details note on Orphan Drug Regulations as per USFDA.
- (8) Enlist names of CIS countries. Explain the legislations of drugs in brief in any one of the same.
- (9) Write a brief note on COPP.

---